CORDIS
EU research results

CORDIS

English EN
Integrating chemical approaches to treat pancreatic cancer: making new leads for a cure

Integrating chemical approaches to treat pancreatic cancer: making new leads for a cure

Objective

Pancreatic ductal adenocarcinoma (PDAC) causes 34000 deaths in the EU every year. Conventional cancer treatments have close to no impact on this disease. As a result, almost all patients diagnosed with PDAC develop metastases and eventually die. Given this poor outlook, the search for new therapeutics is mandatory. These will have to target relevant cancer pathways and be designed based on the available knowledge on the genetic alterations that characterize this malignancy. We propose to build a team composed of clinicians, translational cancer researchers, chemists, and two pharmaceutical enterprises, to synthesize and implement new drugs for PDAC. The focus of the participants in this project will be on pathways and cellular functions broadly involved in PDAC metastasis and immune escape. These drugs are meant to work through diverse and novel modes of action and will be validated using genetically engineered PDAC mouse models that we have established at the Center for Integrated Oncology in Bonn. By creating and exploring diverse classes of compounds capable of arresting tumor growth and of interfering with its metastatic spread, this project will deliver a high number of new molecules with potential as anticancer therapeutics. In particular, our consortium will produce new indoleamine 2,3-dioxygenase-2 (IDO2) inhibitors, galectin-3 inhibitors, edelfosine analogues, inhibitors of the Hippo signaling pathway, alpha-mannosidase inhibitors, SIRT6 inhibitors, and therapeutics acting by synthetic lethality. For compounds with strong proof-of-concept activity, our consortium will perform the Investigational New Drug (IND)-Enabling Studies, with the goal of delivering a new drug ready to be tested clinically by the end of the project. The PANACREAS project is meant to help find better treatments for PDAC, boost research on this form of cancer in the EU, and open new avenues for scientific and technological innovation.
Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Coordinator

UNIVERSITAETSKLINIKUM BONN

Address

Sigmund-Freud-Strasse 25
53127 Bonn

Germany

Activity type

Higher or Secondary Education Establishments

EU Contribution

€ 457 200

Administrative Contact

Beate Becker (Ms.)

Participants (11)

Sort alphabetically

Sort by EU Contribution

Expand all

UNIVERSITA DEGLI STUDI DI GENOVA

Italy

EU Contribution

€ 359 016,53

AGENCIA ESTATAL CONSEJO SUPERIOR DEINVESTIGACIONES CIENTIFICAS

Spain

EU Contribution

€ 276 237,50

ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE

Switzerland

EU Contribution

€ 429 600

CENTRE HOSPITALIER UNIVERSITAIRE VAUDOIS

Switzerland

EU Contribution

€ 269 280

UNIVERSIDAD DE SEVILLA

Spain

EU Contribution

€ 189 280

UNIVERSITA DEGLI STUDI DI TRENTO

Italy

EU Contribution

€ 172 089

LUNDS UNIVERSITET

Sweden

EU Contribution

€ 280 720

DEBIOPHARM S.A.

Switzerland

EU Contribution

€ 47 883,47

APOINTECH SL

Spain

EU Contribution

€ 202 150

ALTA RICERCA E SVILUPPO IN BIOTECNOLOGIE SRLU

Italy

EU Contribution

€ 89 600,50

SIB INSTITUT SUISSE DE BIOINFORMATIQUE

Switzerland

EU Contribution

€ 192 150

Project information

Grant agreement ID: 256986

Status

Closed project

  • Start date

    1 March 2011

  • End date

    29 February 2016

Funded under:

FP7-HEALTH

  • Overall budget:

    € 3 899 823,25

  • EU contribution

    € 2 965 207

Coordinated by:

UNIVERSITAETSKLINIKUM BONN

Germany